UK cost agency rejects Roches new melanoma pill
UK cost agency rejects Roches new melanoma pill LONDON (Reuters) - Swiss group Roches new melanoma drug Zelboraf has been rejected in a preliminary ruling by Britains healthcare cost agency, triggering a fresh clash between the worlds biggest maker of cancer drugs and NICE. The National Institute for Health and Clinical Excellence said on Friday that while Zelboraf was effective for melanoma patients with a particular genetic mutation, its longer-term effect on survival was uncertain. ... //news.yahoo.com/uk-cost-agency-rejects-roches-melanoma-pill-231035066--finance.html
Create Date : 18 มิถุนายน 2555 |
Last Update : 18 มิถุนายน 2555 15:43:04 น. |
|
0 comments
|
Counter : 882 Pageviews. |
|
|
|
|
|